Our Approach to Peptide Education

Conventional Medicine First

We believe in the primacy of conventional, evidence-based medicine. Peptides should never be a first-line treatment or a substitute for working with qualified healthcare providers. If you have a health concern, the appropriate first step is to consult a licensed physician — not to research which peptide might address it.

This is not a disclaimer we add reluctantly. It reflects a genuine editorial principle: we built this resource to provide context for people who are already working with healthcare providers, or who want to understand the scientific literature before a medical conversation — not as a guide to self-treatment.

Our Evidence Grading System

Every peptide profile on this site carries an evidence level rating. This rating reflects the quality and type of research available for that compound. Here is what each level means:

Level A — FDA Approved

The compound has received FDA approval for at least one indication following completion of Phase III clinical trials. Human safety and efficacy data is available for that specific use. Example: PT-141 (Vyleesi) for hypoactive sexual desire disorder.

Level B — Human Clinical Trials Completed

Human clinical trial data exists, but the compound has not achieved FDA approval (may be approved in other countries, or trials completed without seeking US approval). The evidence base is meaningful but may be limited in size or scope. Example: Semax, approved in Russia and Ukraine for cognitive and neurological indications.

Level C — Limited Human Data

Some human trial data exists, but the evidence base is small — often a single small trial, a pilot study, or limited data on safety in humans. Most evidence for mechanism and effects comes from preclinical research. Example: CJC-1295, with some human pharmacokinetic data.

Level D — Animal and In Vitro Studies Only

No completed human clinical trials. All meaningful evidence comes from studies in rodents, other animals, or cell cultures. Animal results frequently do not translate to humans. This is the most common rating for compounds covered on this site. Example: BPC-157, which has extensive rat study data but no published human trials.

The majority of peptides people discuss online as "research chemicals" are Level D compounds. We state this plainly because it matters for how you interpret any information you read about them.

Safety Over Hype

We intentionally lead with safety information and limitations. On every peptide profile, you will find side effects and research gaps discussed prominently — not buried after benefit claims. This is a deliberate editorial choice.

The peptide space has no shortage of enthusiastic content that emphasizes benefits while minimizing or omitting risks. Our goal is to provide the information needed for genuinely informed decisions, which requires an honest accounting of what is not known as much as what is.

Transparency About Evidence Quality

We disclose the quality of evidence for every claim. When data comes only from animal studies, we say so clearly. When a mechanism has been observed in vitro but not confirmed in vivo, we note the distinction. When human trials are small, industry-funded, or have methodological limitations, we disclose that.

We do not present animal study results as though they were human results. We do not omit negative findings. When the evidence for a benefit claim is weak, we say so — even if that conflicts with the narrative common in online communities.

Not Medical Advice or Recommendations

Nothing on this site constitutes medical advice, a treatment recommendation, or an endorsement of any compound for human use. This includes content framed as "how to use," "dosage," or "protocol" information — which we present only to describe what appears in research literature, not to guide personal use.

We describe what researchers have studied. We do not recommend that readers use any compound based on that research.

How to Use This Site Effectively

If you are using this site to prepare for a conversation with your doctor, here is a practical approach:

1. Check the evidence level first. Before reading about benefits, understand what kind of research supports those claims. A Level D rating means the evidence is preliminary.
2. Read the side effects section. Every profile includes known and potential adverse effects. These are often underreported in popular peptide content.
3. Note the research gaps. Each profile discusses what is not known. Understanding the limits of current knowledge is as important as understanding what has been studied.
4. Bring the references to your appointment. Our reference sections cite the primary research. A physician can review the original studies and contextualize them against your specific health situation.
5. Ask about conventional options first. For any health goal you are researching, ask your provider about established, approved treatments before discussing experimental compounds.

For more on working with a healthcare provider, see our guide on finding a qualified provider.